PFIZER - Pfizer Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

PFIZER

48/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹4592.50+64.60(+1.43%)

Market Closed as of Jun 9, 2026, 15:30 IST

Select time range

Pros

Technicals: Bullish SharesGuru indicator.

Smart Money: Smart money has been increasing their position in the stock.

Size: Market Cap wise it is among the top 20% companies of india.

Balance Sheet: Strong Balance Sheet.

Dividend: Pays a strong dividend yield of 4.36%.

Profitability: Very strong Profitability. One year profit margin are 27%.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

Past Returns: In past three years, the stock has provided 4.7% return compared to 7.6% by NIFTY 50.

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

PFIZER - Pfizer Ltd. Share Price

Pharmaceuticals & Biotechnology

Sharesguru Stock Score

PFIZER

48/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

₹4592.50+64.60(+1.43%)

Market Closed as of Jun 9, 2026, 15:30 IST

Select time range

Pros

Technicals: Bullish SharesGuru indicator.

Smart Money: Smart money has been increasing their position in the stock.

Size: Market Cap wise it is among the top 20% companies of india.

Balance Sheet: Strong Balance Sheet.

Dividend: Pays a strong dividend yield of 4.36%.

Profitability: Very strong Profitability. One year profit margin are 27%.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

Past Returns: In past three years, the stock has provided 4.7% return compared to 7.6% by NIFTY 50.

Valuation
Market Cap	20.39 kCr
Price/Earnings (Trailing)	28.22
Price/Sales (Trailing)	7.53
EV/EBITDA	19.45
Price/Free Cashflow	21.63
MarketCap/EBT	20.89
Enterprise Value	20.29 kCr

Fundamentals
Revenue (TTM)	2.71 kCr
Rev. Growth (Yr)	5.3%
Earnings (TTM)	722.43 Cr
Earnings Growth (Yr)	-39.6%

Profitability
Operating Margin	38%
EBT Margin	36%
Return on Equity	17.19%
Return on Assets	14.68%
Free Cashflow Yield	4.62%

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns
Price Change 1W	0.30%
Price Change 1M	-6%
Price Change 6M	-9.9%
Price Change 1Y	-20.6%
3Y Cumulative Return	4.7%
5Y Cumulative Return	-3.4%
7Y Cumulative Return	5.3%
10Y Cumulative Return	9.4%

Cash Flow & Liquidity
Cash Flow from Investing (TTM)	-561.67 Cr
Cash Flow from Operations (TTM)	967.57 Cr
Cash Flow from Financing (TTM)	-798.31 Cr
Cash & Equivalents	102.66 Cr
Free Cash Flow (TTM)	942.34 Cr
Free Cash Flow/Share (TTM)	205.99

Balance Sheet
Total Assets	4.92 kCr
Total Liabilities	718.98 Cr
Shareholder Equity	4.2 kCr
Current Assets	3.8 kCr
Current Liabilities	627.48 Cr
Net PPE	136.13 Cr
Inventory	472.66 Cr
Goodwill	527.49 Cr

Capital Structure & Leverage
Debt Ratio	0.00
Debt/Equity	0.00
Interest Coverage	101.92
Interest/Cashflow Ops	103.06

Dividend & Shareholder Returns
Dividend/Share (TTM)	200
Dividend Yield	4.36%
Shares Dilution (1Y)	0.00%
Shares Dilution (3Y)	0.00%

Sharesguru Stock Score

PFIZER

48/100

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 4 years

Pros

Technicals: Bullish SharesGuru indicator.

Smart Money: Smart money has been increasing their position in the stock.

Size: Market Cap wise it is among the top 20% companies of india.

Balance Sheet: Strong Balance Sheet.

Dividend: Pays a strong dividend yield of 4.36%.

Profitability: Very strong Profitability. One year profit margin are 27%.

Buy Backs: Company has bought back it's stock in the past which is a good thing.

Cons

Momentum: Stock has a weak negative price momentum.

Past Returns: In past three years, the stock has provided 4.7% return compared to 7.6% by NIFTY 50.

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Rank

Balance Sheet

Momentum

Technicals

Smart Money

Insider Trading

Investor Care
Dividend Yield	4.36%
Dividend/Share (TTM)	200
Shares Dilution (1Y)	0.00%
Earnings/Share (TTM)	157.92

Financial Health
Current Ratio	6.06
Debt/Equity	0.00

Technical Indicators
RSI (14d)	23.2
RSI (5d)	53.18
RSI (21d)	42.28
MACD Signal	Sell
Stochastic Oscillator Signal	Buy
SharesGuru Signal	Buy
RSI Signal	Buy
RSI5 Signal	Hold
RSI21 Signal	Hold
SMA 5 Signal	Buy
SMA 10 Signal	Sell
SMA 20 Signal	Sell
SMA 50 Signal	Sell
SMA 100 Signal	Sell

Earnings Outlook

Q&A Session

Share Holdings

Understand Pfizer ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
PFIZER EAST INDIA B V	39.75%
WYETH LLC	12.28%
NIPPON LIFE INDIA TRUSTEE LIMITED	4.16%
LIFE INSURANCE CORPORATION OF INDIA	3.85%
WYETH HOLDINGS CORPORATION	3.56%
WARNER-LAMBERT COMPANY LLC	2.6%
QUANT MUTUAL FUND	2.22%
ICICI PRUDENTIAL FUND	2.16%
ATUL LIMITED	2.1%
PARKE, DAVIS & COMPANY LLC	2.09%
JOHN WYETH & BROTHER LTD	1.93%
PHARMACIA CORPORATION	1.71%
FOREIGN INSTITUTIONAL INVESTORS	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr

Category	PFIZER	Pharmaceuticals
PE	28.22	35.88
PS	7.53	4.94
Growth	10.4 %	10.7 %

Key Insights

1. PFIZER is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.6% in Pharmaceuticals.
3. The company is growing at an average growth rate of other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	10.5%	2,520	2,281	2,193	2,425	2,611	2,239
Other Income	9.4%	188	172	181	101	63	81
Total Income	10.4%	2,708	2,454	2,374	2,526	2,674	2,320
Cost of Materials	14%	310	272	336	345	354	335
Purchases of stock-in-trade	18.6%	608	513	469	472	667	449
Employee Expense	-0.8%	368	371	348	332	404	361
Finance costs	14.4%	9.48	8.41	15	13	10	15
Depreciation and Amortization	-5%	58	61	62	106	115	109
Other expenses	1.1%	363	359	418	411	424	368
Total Expenses	4.5%	1,683	1,610	1,636	1,735	1,901	1,651
Profit Before exceptional items and Tax	21.6%	1,025	843	738	791	773	669
Exceptional items before tax	-129.2%	-49.16	173	7.95	33	0	0
Total profit before tax	-3.9%	976	1,016	746	824	773	669
Current tax	-2.3%	258	264	159	252	218	184
Deferred tax	68.2%	-4.28	-15.61	36	-51.74	-58	-12.52
Total tax	2%	253	248	195	200	160	171
Total profit (loss) for period	-6%	722	768	551	624	613	498
Other comp. income net of taxes	1192.3%	3.84	0.74	5.45	3.61	7.17	-0.96
Total Comprehensive Income	-5.5%	726	768	557	628	620	497
Earnings Per Share, Basic	-5.9%	157.92	167.79	120.51	136.38	133.89	108.77
Earnings Per Share, Diluted	-5.9%	157.92	167.79	120.51	136.38	133.89	108.77

Description	(%) Q/Q	Mar-2026	Dec-2025	Jun-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	-2.5%	629	645	603	538	589	563
Other Income	8.1%	41	38	67	43	43	42
Total Income	-1.9%	670	683	670	581	632	605
Cost of Materials	22.4%	83	68	89	67	77	58
Purchases of stock-in-trade	-18.8%	118	145	124	105	81	188
Employee Expense	-23.2%	77	100	96	96	101	91
Finance costs	12.1%	2.11	1.99	3.25	1.51	2.1	2.11
Depreciation and Amortization	7.7%	15	14	14	15	15	15
Other expenses	4.4%	96	92	86	99	88	93
Total Expenses	-5.3%	410	433	411	408	416	402
Profit Before exceptional items and Tax	4%	260	250	260	172	215	203
Exceptional items before tax	113.6%	9.04	-58.2	0	0	0	0
Total profit before tax	40.3%	269	192	260	172	215	203
Current tax	15.8%	67	58	67	50	60	55
Deferred tax	115.3%	2.36	-7.89	0.39	-5.26	-3.01	-3.14
Total tax	38.8%	69	50	68	45	57	52
Total profit (loss) for period	41.1%	200	142	192	128	158	151
Other comp. income net of taxes	221.8%	3.8	1.87	-0.92	-0.54	-0.53	-0.54
Total Comprehensive Income	42%	204	144	191	127	158	150
Earnings Per Share, Basic	42.2%	43.68	31.01	41.91	27.89	34.61	32.94
Earnings Per Share, Diluted	42.2%	43.68	31.01	41.91	27.89	0	32.94

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	-50%	103	205	495	35	112	16
Loans, current	-	0	0	0	0	0	0
Total current financial assets	11.7%	3,296	2,950	2,998	2,531	2,247	2,082
Inventories	-5.4%	473	500	476	455	434	399
Total current assets	9.4%	3,803	3,477	3,513	3,023	2,738	2,518
Property, plant and equipment	-12.3%	136	155	172	132	151	164
Capital work-in-progress	192.3%	20	7.5	7.64	2.82	0.4	9.38
Investment property	-	0	0	0	0	0	0
Goodwill	0%	527	527	527	527	527	527
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	7.7%	15	14	14	12	14	13
Total non-current assets	-0.9%	1,119	1,129	1,398	1,404	1,459	1,457
Total assets	6.9%	4,922	4,606	4,911	4,459	4,229	4,006
Total non-current financial liabilities	-8.7%	43	47	68	38	0	73
Provisions, non-current	-26.6%	48	65	57	65	0	46
Total non-current liabilities	-18%	92	112	124	103	87	119
Borrowings, current	0%	2.5	2.5	2.5	2.5	2.5	2.5
Total current financial liabilities	0.9%	320	317	232	281	206	323
Provisions, current	-35.6%	30	46	51	57	45	93
Current tax liabilities	-9.8%	232	257	221	182	160	164
Total current liabilities	-2.9%	627	646	570	605	547	614
Total liabilities	-5%	719	757	694	708	633	733
Equity share capital	0%	46	46	46	46	46	46
Total equity	9.2%	4,203	3,848	4,217	3,751	3,596	3,273
Total equity and liabilities	6.9%	4,922	4,606	4,911	4,459	4,229	4,006

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	-113.5%	0	8.41	15	0	10	-
Change in inventories	39.4%	-25.21	-42.22	-16	22	-13.86	-
Depreciation	-5%	58	61	62	106	115	-
Unrealised forex losses/gains	-26.6%	0	0.21	-0.32	0	0	-
Adjustments for interest income	-	166	0	172	85	49	-
Share-based payments	0%	14	14	14	13	12	-
Net Cashflows from Operations	-2.1%	953	973	411	854	893	-
Interest received	99.4%	0	-157.27	0	0	0	-
Income taxes paid (refund)	-110%	-14.53	156	154	303	226	-
Other inflows (outflows) of cash	-	0	0	0	-195.31	0	-
Net Cashflows From Operating Activities	46.7%	968	660	257	356	667	-
Proceeds from sales of PPE	120%	1.16	0.2	0.02	1.22	2.06	-
Purchase of property, plant and equipment	-11.1%	25	28	19	65	15	-
Proceeds from sales of long-term assets	-100.7%	0	152	53	0	0	-
Interest received	27.5%	177	139	129	71	44	-
Other inflows (outflows) of cash	-113.3%	-714.59	-334.43	-109.1	-43.4	-605.54	-
Net Cashflows From Investing Activities	-677.8%	-561.67	-71.34	54	-36.05	-575.02	-
Payments of lease liabilities	-15.9%	38	45	41	35	0	-
Dividends paid	372.3%	752	160	183	297	160	-
Interest paid	1171.4%	8.5	0.3	11	13	0.78	-
Other inflows (outflows) of cash	-	0	0	0	-0.63	-19.99	-
Net Cashflows from Financing Activities	-287.4%	-798.31	-205.34	-235.14	-345.79	-180.51	-
Net change in cash and cash eq.	-203%	-392.41	383	75	-26.14	-88.45	-

Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.

Industry Group:Pharmaceuticals & Biotechnology

Employees:1,721

Website:www.pfizerltd.co.in

Important Disclosure & Data Context

This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.

Earnings Outlook

Q&A Session

Share Holdings

Understand Pfizer ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.

Holding Pattern

Major Shareholders

Share Holding Details

Shareholder Name	Holding %
PFIZER EAST INDIA B V	39.75%
WYETH LLC	12.28%
NIPPON LIFE INDIA TRUSTEE LIMITED	4.16%
LIFE INSURANCE CORPORATION OF INDIA	3.85%
WYETH HOLDINGS CORPORATION	3.56%
WARNER-LAMBERT COMPANY LLC	2.6%
QUANT MUTUAL FUND	2.22%
ICICI PRUDENTIAL FUND	2.16%
ATUL LIMITED	2.1%
PARKE, DAVIS & COMPANY LLC	2.09%
JOHN WYETH & BROTHER LTD	1.93%
PHARMACIA CORPORATION	1.71%
FOREIGN INSTITUTIONAL INVESTORS	0%

Overall Distribution

Distribution across major stakeholders

Ownership Distribution

Distribution across major institutional holders

Ticker	Name	Mkt Cap	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr

Category	PFIZER	Pharmaceuticals
PE	28.22	35.88
PS	7.53	4.94
Growth	10.4 %	10.7 %

Key Insights

1. PFIZER is NOT among the Top 10 largest companies in Pharmaceuticals.
2. The company holds a market share of 0.6% in Pharmaceuticals.
3. The company is growing at an average growth rate of other Pharmaceuticals companies.

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Revenue From Operations	10.5%	2,520	2,281	2,193	2,425	2,611	2,239
Other Income	9.4%	188	172	181	101	63	81
Total Income	10.4%	2,708	2,454	2,374	2,526	2,674	2,320
Cost of Materials	14%	310	272	336	345	354	335
Purchases of stock-in-trade	18.6%	608	513	469	472	667	449
Employee Expense	-0.8%	368	371	348	332	404	361
Finance costs	14.4%	9.48	8.41	15	13	10	15
Depreciation and Amortization	-5%	58	61	62	106	115	109
Other expenses	1.1%	363	359	418	411	424	368
Total Expenses	4.5%	1,683	1,610	1,636	1,735	1,901	1,651
Profit Before exceptional items and Tax	21.6%	1,025	843	738	791	773	669
Exceptional items before tax	-129.2%	-49.16	173	7.95	33	0	0
Total profit before tax	-3.9%	976	1,016	746	824	773	669
Current tax	-2.3%	258	264	159	252	218	184
Deferred tax	68.2%	-4.28	-15.61	36	-51.74	-58	-12.52
Total tax	2%	253	248	195	200	160	171
Total profit (loss) for period	-6%	722	768	551	624	613	498
Other comp. income net of taxes	1192.3%	3.84	0.74	5.45	3.61	7.17	-0.96
Total Comprehensive Income	-5.5%	726	768	557	628	620	497
Earnings Per Share, Basic	-5.9%	157.92	167.79	120.51	136.38	133.89	108.77
Earnings Per Share, Diluted	-5.9%	157.92	167.79	120.51	136.38	133.89	108.77

Description	(%) Q/Q	Mar-2026	Dec-2025	Jun-2025	Dec-2024	Sep-2024	Jun-2024
Revenue From Operations	-2.5%	629	645	603	538	589	563
Other Income	8.1%	41	38	67	43	43	42
Total Income	-1.9%	670	683	670	581	632	605
Cost of Materials	22.4%	83	68	89	67	77	58
Purchases of stock-in-trade	-18.8%	118	145	124	105	81	188
Employee Expense	-23.2%	77	100	96	96	101	91
Finance costs	12.1%	2.11	1.99	3.25	1.51	2.1	2.11
Depreciation and Amortization	7.7%	15	14	14	15	15	15
Other expenses	4.4%	96	92	86	99	88	93
Total Expenses	-5.3%	410	433	411	408	416	402
Profit Before exceptional items and Tax	4%	260	250	260	172	215	203
Exceptional items before tax	113.6%	9.04	-58.2	0	0	0	0
Total profit before tax	40.3%	269	192	260	172	215	203
Current tax	15.8%	67	58	67	50	60	55
Deferred tax	115.3%	2.36	-7.89	0.39	-5.26	-3.01	-3.14
Total tax	38.8%	69	50	68	45	57	52
Total profit (loss) for period	41.1%	200	142	192	128	158	151
Other comp. income net of taxes	221.8%	3.8	1.87	-0.92	-0.54	-0.53	-0.54
Total Comprehensive Income	42%	204	144	191	127	158	150
Earnings Per Share, Basic	42.2%	43.68	31.01	41.91	27.89	34.61	32.94
Earnings Per Share, Diluted	42.2%	43.68	31.01	41.91	27.89	0	32.94

Description	(%) Q/Q	Mar-2026	Sep-2025	Mar-2025	Sep-2024	Mar-2024	Sep-2023
Cash and cash equivalents	-50%	103	205	495	35	112	16
Loans, current	-	0	0	0	0	0	0
Total current financial assets	11.7%	3,296	2,950	2,998	2,531	2,247	2,082
Inventories	-5.4%	473	500	476	455	434	399
Total current assets	9.4%	3,803	3,477	3,513	3,023	2,738	2,518
Property, plant and equipment	-12.3%	136	155	172	132	151	164
Capital work-in-progress	192.3%	20	7.5	7.64	2.82	0.4	9.38
Investment property	-	0	0	0	0	0	0
Goodwill	0%	527	527	527	527	527	527
Loans, non-current	-	0	0	0	0	0	0
Total non-current financial assets	7.7%	15	14	14	12	14	13
Total non-current assets	-0.9%	1,119	1,129	1,398	1,404	1,459	1,457
Total assets	6.9%	4,922	4,606	4,911	4,459	4,229	4,006
Total non-current financial liabilities	-8.7%	43	47	68	38	0	73
Provisions, non-current	-26.6%	48	65	57	65	0	46
Total non-current liabilities	-18%	92	112	124	103	87	119
Borrowings, current	0%	2.5	2.5	2.5	2.5	2.5	2.5
Total current financial liabilities	0.9%	320	317	232	281	206	323
Provisions, current	-35.6%	30	46	51	57	45	93
Current tax liabilities	-9.8%	232	257	221	182	160	164
Total current liabilities	-2.9%	627	646	570	605	547	614
Total liabilities	-5%	719	757	694	708	633	733
Equity share capital	0%	46	46	46	46	46	46
Total equity	9.2%	4,203	3,848	4,217	3,751	3,596	3,273
Total equity and liabilities	6.9%	4,922	4,606	4,911	4,459	4,229	4,006

Description	(%) Q/Q	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Finance costs	-113.5%	0	8.41	15	0	10	-
Change in inventories	39.4%	-25.21	-42.22	-16	22	-13.86	-
Depreciation	-5%	58	61	62	106	115	-
Unrealised forex losses/gains	-26.6%	0	0.21	-0.32	0	0	-
Adjustments for interest income	-	166	0	172	85	49	-
Share-based payments	0%	14	14	14	13	12	-
Net Cashflows from Operations	-2.1%	953	973	411	854	893	-
Interest received	99.4%	0	-157.27	0	0	0	-
Income taxes paid (refund)	-110%	-14.53	156	154	303	226	-
Other inflows (outflows) of cash	-	0	0	0	-195.31	0	-
Net Cashflows From Operating Activities	46.7%	968	660	257	356	667	-
Proceeds from sales of PPE	120%	1.16	0.2	0.02	1.22	2.06	-
Purchase of property, plant and equipment	-11.1%	25	28	19	65	15	-
Proceeds from sales of long-term assets	-100.7%	0	152	53	0	0	-
Interest received	27.5%	177	139	129	71	44	-
Other inflows (outflows) of cash	-113.3%	-714.59	-334.43	-109.1	-43.4	-605.54	-
Net Cashflows From Investing Activities	-677.8%	-561.67	-71.34	54	-36.05	-575.02	-
Payments of lease liabilities	-15.9%	38	45	41	35	0	-
Dividends paid	372.3%	752	160	183	297	160	-
Interest paid	1171.4%	8.5	0.3	11	13	0.78	-
Other inflows (outflows) of cash	-	0	0	0	-0.63	-19.99	-
Net Cashflows from Financing Activities	-287.4%	-798.31	-205.34	-235.14	-345.79	-180.51	-
Net change in cash and cash eq.	-203%	-392.41	383	75	-26.14	-88.45	-

Industry Group:Pharmaceuticals & Biotechnology

Employees:1,721

Website:www.pfizerltd.co.in

PFIZER - Pfizer Ltd. Share Price

PFIZER

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

PFIZER

PFIZER - Pfizer Ltd. Share Price

PFIZER

Valuation

Fundamentals

Profitability

Price to Sales Ratio

Revenue (Last 12 mths)

Net Income (Last 12 mths)

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

PFIZER

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Pfizer Ltd. do?

Important Disclosure & Data Context

Valuation

Fundamentals

Profitability

Growth & Returns

Cash Flow & Liquidity

Balance Sheet

Capital Structure & Leverage

Dividend & Shareholder Returns

Investor Care

Financial Health

Technical Indicators

Share Holdings

Holding Pattern

Share Holding Details

Overall Distribution

Ownership Distribution

What does Pfizer Ltd. do?

Important Disclosure & Data Context